Intestinal immune network for IgA production

The intestinal IgA secretion pathway, scientifically known as the intestinal immune network for IgA production (KEGG: hsa04672), is a specialized immune process responsible for generating and transporting secretory IgA (SIgA) into the gut lumen (KEGG, 2024). This pathway begins in gut-associated lymphoid tissues (GALT), such as Peyer's patches, where B cells are induced to undergo class-switch recombination to IgA, primarily driven by cytokines like TGF-beta, BAFF, and APRIL (NIH, 2023). Following maturation into plasma cells in the lamina propria, dimeric IgA is produced and subsequently transported across the intestinal epithelium by the polymeric immunoglobulin receptor (pIgR) (NIH, 2021). SIgA serves as a critical first line of defense by neutralizing pathogens and maintaining the homeostasis of the intestinal microbiota (MDPI, 2020). Dysregulation of this pathway is central to the pathogenesis of IgA nephropathy, where the overproduction of galactose-deficient IgA1 (Gd-IgA1) leads to the formation of nephritogenic immune complexes (Fresenius Medical Care, 2023). Therapeutic interventions targeting this pathway include local-acting corticosteroids like budesonide, which suppress GALT activity, and biologics that inhibit BAFF and APRIL to reduce the production of pathogenic IgA (NIH, 2024). Monitoring efficacy often involves measuring levels of Gd-IgA1 and proteinuria, while safety concerns focus on potential immunosuppression and infection risk (NIH, 2022).

Other names

Intestinal IgA secretion pathwayMucosal IgA production pathwayGut-associated lymphoid tissue (GALT) IgA pathwayIgA secretion pathway

Inhibition of BAFF and APRIL, suppression of B-cell activation in Peyer's patches, reduction of galactose-deficient IgA1 production, and inhibition of plasma cell survival.